Fortress Biotech market cap is $307.5 m, and annual revenue was $45.6 m in FY 2020

Fortress Biotech Gross profit (Q1, 2021)7.7 M

Fortress Biotech Gross profit margin (Q1, 2021), %66.3%

Fortress Biotech Net income (Q1, 2021)-26.1 M

Fortress Biotech EBIT (Q1, 2021)-30 M

Fortress Biotech Cash, 31-Mar-2021289.9 M

Fortress Biotech EV110.1 M

Fortress Biotech revenue was $45.6 m in FY, 2020

Fortress Biotech revenue breakdown by business segment: 18.7% from Other Branded, 76.6% from Targadox and 4.7% from Other

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Revenue | 187.6m | 26.9m | 36.6m | 45.6m |

| (86%) | 36% | ||

## Cost of goods sold | 3.7m | 6.1m | 10.5m | 14.6m |

## Gross profit | 183.9m | 20.8m | 26.1m | 31.0m |

| 98% | 77% | 71% | 68% |

## R&D expense | 56.7m | 87.4m | 81.3m | 2.8m |

## General and administrative expense | 40.5m | 53.4m | 55.6m | 61.2m |

## Operating expense total | 285.1m | 140.8m | 136.9m | 125.3m |

## EBIT | (101.2m) | (120.0m) | (110.8m) | (94.3m) |

| (54%) | (446%) | (303%) | (207%) |

## Interest expense | 7.9m | 8.5m | ||

## Interest income | 819.0k | 1.1m | 2.6m | 1.5m |

## Pre tax profit | (98.3m) | (141.9m) | (101.7m) | (102.8m) |

## Income tax expense | 1.5m | 100.0k | ||

## Net Income | (99.8m) | (141.9m) | (101.7m) | (103.0m) |

## EPS | (1.6) | (1.9) | (0.7) |

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Cash | 113.9m | 65.5m | 136.9m | 233.4m |

## Accounts Receivable | 7.8m | 5.5m | 13.5m | 19.3m |

## Prepaid Expenses | 12.7m | 6.7m | 4.1m | 6.7m |

## Inventories | 171.0k | 678.0k | 857.0k | 1.4m |

## Current Assets | 183.2m | 111.2m | 156.3m | 261.6m |

## PP&E | 9.5m | 12.0m | 12.4m | 11.9m |

## Goodwill | 18.6m | |||

## Total Assets | 246.0m | 141.0m | 226.4m | 328.8m |

## Accounts Payable | 36.1m | 34.1m | 35.5m | 40.7m |

## Short-term debt | 14.2m | 20.4m | 10.1m | 1.8m |

## Current Liabilities | 67.4m | 55.6m | 45.6m | 48.0m |

## Long-term debt | 43.2m | 60.4m | 101.1m | 74.6m |

## Total Debt | 57.4m | 80.8m | 111.3m | 76.4m |

## Total Liabilities | 125.4m | 121.3m | 153.9m | 131.8m |

## Common Stock | 551.0k | 717.0k | 574.0k | 95.0k |

## Preferred Stock | 1.0k | 1.0k | 1.0k | 3.0k |

## Additional Paid-in Capital | 364.1m | 397.4m | 461.9m | 583.0m |

## Retained Earnings | (312.1m) | (396.3m) | (436.2m) | (482.8m) |

## Total Equity | 120.5m | 19.7m | 72.5m | 197.0m |

## Debt to Equity Ratio | 0.5 x | 4.1 x | 1.5 x | |

## Debt to Assets Ratio | 0.2 x | 0.6 x | 0.5 x | |

## Financial Leverage | 2 x | 7.1 x | 3.1 x | 1.7 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Net Income | (99.8m) | (141.9m) | (101.7m) | (103.0m) |

## Depreciation and Amortization | 2.8m | 1.4m | 1.9m | 3.7m |

## Accounts Receivable | (5.9m) | 2.3m | (8.1m) | (5.9m) |

## Inventories | 32.0k | (507.0k) | (179.0k) | (547.0k) |

## Accounts Payable | 9.7m | 4.7m | 2.1m | 6.5m |

## Cash From Operating Activities | (85.4m) | (98.8m) | (95.0m) | (83.7m) |

## Purchases of PP&E | (2.1m) | (7.1m) | (2.3m) | (1.9m) |

## Cash From Investing Activities | (41.6m) | 18.8m | 20.1m | (7.2m) |

## Long-term Borrowings | (3.6m) | (1.9m) | (134.0k) | |

## Dividends Paid | (299.0k) | (2.3m) | (2.6m) | (237.0k) |

## Cash From Financing Activities | 154.2m | 50.6m | 146.7m | 172.4m |

## Net Change in Cash | 27.1m | (29.4m) | 71.9m | 81.6m |

## Interest Paid | 8.2m |

USD | Q2, 2013 |
---|---|

## Debt/Equity | 0.3 x |

## Debt/Assets | 0.2 x |

## Financial Leverage | 1.4 x |